Sanofi snags another U.S. biotech asset with $3.7 billion deal for Principia Biopharma By Reuters

Sanofi snags another U.S. biotech asset with $3.7 billion deal

© Reuters. FILE PHOTO: Sanofi logo is seen in Paris

By Sudip Kar-Gupta

PARIS (Reuters) – Sanofi SA (PA:) is to buy U.S.-based Principia Biopharma Inc (O:) for around $3.7 billion, the companies announced on Monday, marking the French healthcare company’s latest acquisition in the biotech sector.

The deal will strengthen Sanofi’s research capabilities in areas such as autoimmune and allergic diseases, the companies said, and will see the French company buy the outstanding shares of Principia for $100 per share in cash.

That represents an aggregate equity value of around $3.68 billion on a fully diluted basis and a premium of 10% to Principia Biopharma’s closing price of $90.74 on Aug. 14.

“This acquisition advances our ongoing R&D transformation to accelerate development of the most promising medicines that will address significant patient needs,” said Sanofi Chief Executive Paul Hudson (NYSE:).

Sanofi shares edged up 0.6% in early session trading, bucking a slight fall in France’s CAC-40 index (), as analysts were positive on the deal.

“We like the relatively low risk value accretion of this deal with longer-term optionality, that fits within the strategy of deploying firepower across numerous bolt-on deals,” wrote brokerage Jefferies (NYSE:), which kept a ‘buy’ rating on Sanofi.

Sanofi said it expected to complete the acquisition in the fourth quarter of 2020. 

“The merger will provide global resources to get these novel therapies to patients faster,” said Martin Babler, president and chief executive at Principia Biopharma.

Sanofi shares are down by around 5% since the start of 2020, whereas the CAC-40 has fallen around 17% this year.

The acquisition of Principia Biopharma follows the French company’s 2018 takeover of U.S. haemophilia treatment specialist Bioverativ for $11.6 billion, and its purchase of biotechnology company Synthorx in December 2019 for around $2.5 billion.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

About us

InvestLab is a financial services technology company focused on the global trading market. Founded in 2010 in Hong Kong, the company develops trading, market data, and social research products that enable individual investors and small to mid-size brokers to access global markets. We provide brokers and financial institutions cross border capabilities for retail investors into 43 markets globally.